人乳头瘤病毒疫苗接种覆盖率对美国目前年龄在12岁及以下女孩一生中宫颈癌负担的估计影响。
The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States.
作者信息
Chesson Harrell W, Ekwueme Donatus U, Saraiya Mona, Dunne Eileen F, Markowitz Lauri E
机构信息
From the *Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA; and †Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
出版信息
Sex Transm Dis. 2014 Nov;41(11):656-9. doi: 10.1097/OLQ.0000000000000199.
Abstract
Using a previously published dynamic model, we illustrate the potential benefits of human papillomavirus vaccination among girls currently 12 years or younger in the United States. Increasing vaccine coverage of young girls to 80% would avert 53,300 lifetime cervical cancer cases versus 30% coverage and 28,800 cases versus 50% coverage.
摘要
利用一个先前发表的动态模型，我们阐述了人乳头瘤病毒疫苗接种对于美国目前12岁及以下女孩的潜在益处。将年轻女孩的疫苗接种覆盖率提高到80%，相对于30%的覆盖率可避免53300例宫颈癌终生病例，相对于50%的覆盖率可避免28800例。
相似文献
1
The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States.
Sex Transm Dis. 2014 Nov;41(11):656-9. doi: 10.1097/OLQ.0000000000000199.
2
Correlates of human papillomavirus vaccine coverage: a state-level analysis.
Sex Transm Dis. 2015 Feb;42(2):71-5. doi: 10.1097/OLQ.0000000000000225.
3
Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Lancet Glob Health. 2014 Jul;2(7):e406-14. doi: 10.1016/S2214-109X(14)70237-2. Epub 2014 Jun 9.
4
Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
Value Health. 2012 Jul-Aug;15(5):622-31. doi: 10.1016/j.jval.2012.02.012. Epub 2012 Jun 12.
5
Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Vaccine. 2015 May 7;33 Suppl 1:A135-42. doi: 10.1016/j.vaccine.2014.12.031.
6
Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
BMC Public Health. 2012 Oct 13;12:872. doi: 10.1186/1471-2458-12-872.
7
Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Vaccine. 2015 May 7;33 Suppl 1:A167-73. doi: 10.1016/j.vaccine.2014.12.067.
8
A brief history of economic evaluation for human papillomavirus vaccination policy.
Sex Health. 2010 Sep;7(3):352-8. doi: 10.1071/SH10018.
9
Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
Cancer. 2017 Sep 1;123(17):3253-3260. doi: 10.1002/cncr.30734. Epub 2017 May 4.
10
Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
PLoS One. 2020 Mar 23;15(3):e0230359. doi: 10.1371/journal.pone.0230359. eCollection 2020.
引用本文的文献
1
Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.
Vaccine. 2018 Jul 5;36(29):4362-4368. doi: 10.1016/j.vaccine.2018.04.071.
2
Improving Physician Recommendations for Human Papillomavirus Vaccination: The Role of Professional Organizations.
Sex Transm Dis. 2017 Jan;44(1):42-47. doi: 10.1097/OLQ.0000000000000543.
3
The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
Hum Vaccin Immunother. 2016 Jun 2;12(6):1363-72. doi: 10.1080/21645515.2016.1140288. Epub 2016 Feb 18.
本文引用的文献
1
Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.
MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):620-4.
2
National and state vaccination coverage among adolescents aged 13-17 years--United States, 2012.
MMWR Morb Mortal Wkly Rep. 2013 Aug 30;62(34):685-93.
3
Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395. Epub 2012 Oct 27.
4
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
Lancet Infect Dis. 2012 Oct;12(10):781-9. doi: 10.1016/S1473-3099(12)70187-1. Epub 2012 Aug 22.
5
Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Vaccine. 2012 Sep 14;30(42):6016-9. doi: 10.1016/j.vaccine.2012.07.056. Epub 2012 Aug 4.
6
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.
J Natl Cancer Inst. 2011 Oct 5;103(19):1444-51. doi: 10.1093/jnci/djr319. Epub 2011 Sep 9.
7
The cost-effectiveness of male HPV vaccination in the United States.
Vaccine. 2011 Oct 26;29(46):8443-50. doi: 10.1016/j.vaccine.2011.07.096. Epub 2011 Aug 2.
8
Impact of vaccinating boys and men against HPV in the United States.
Vaccine. 2010 Oct 4;28(42):6858-67. doi: 10.1016/j.vaccine.2010.08.030. Epub 2010 Aug 14.
9
Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.
Vaccine. 2010 Jul 26;28(33):5473-84. doi: 10.1016/j.vaccine.2010.05.056. Epub 2010 Jun 2.
10
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
BMJ. 2009 Oct 8;339:b3884. doi: 10.1136/bmj.b3884.
Zotero 插件